Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | PTAFR | P25105 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19393075 | 0.89 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL2693388 | 0.85 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3TSHREPHX1 | |
| SCHEMBL25356229 | 0.81 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3PTAFR | |
| SCHEMBL10560327 | 0.79 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3TSHRCYP2A6 | |
| SCHEMBL10560314 | 0.79 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3TSHRCYP2A6 | |
| SCHEMBL9232025 | 0.79 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3TSHRCYP2A6 | |
| SCHEMBL19392979 | 0.78 | CHRM2 (0.50) | TSHRCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL8643269 | 0.77 | TSHR (0.39) | SLC6A2SLC6A4SLC6A3TSHREPHX1 | |
| SCHEMBL7849315 | 0.74 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3TSHRCHRM2 | |
| SCHEMBL18055936 | 0.74 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3TSHRCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | SLC6A2 4169/4885SLC6A4 4539/4885SLC6A3 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.